Elihu EsteyDivision of Hematology, University of Washington School of Medicine, Seattle, WA, USA F1000 Faculty Member (since 31 October 2011)
Professor of Medicine, Division of Hematology, University of Washington
Member, Fred Hutchinson Cancer Research Center
AB Yale University, New Haven, Connecticut (USA)
MD Johns Hopkins University, Baltimore, Maryland (USA)
Member of the American Society of Hematology (USA)
Member of the American Society of Clinical Oncology Board (USA)
Member of the Board MDS Foundation (USA)
Member of the Southwest Oncology Group (USA)
Clinical Trials in AML (particularly those involving new research designs):
New designs for clinical trials - patients and physician are poorly served by the current phase 1-phase 2-phase 3 paradigm. I am interested in methodology that (a) simultaneously monitors multiple endpoints (such as response and toxicity, or CR and survival), and (b) focuses on small randomized trials to select a therapy to move to a later stage of testing; although such play-the-winner trials are often viewed as "underpowered" they can be shown to be preferable to trials that test only 1 new therapy, because the latter ignore that the worst false negative results from not studying a drug at all, given the role of empiricism in drug development.
Management of Patients with AML:
Numerous questions face clinicians caring for patients with AML. For example, is it reasonable to discharge a patient with a low neutrophil count, is a day 14 marrow really necessary, how well do I know this patients' prognosis with standard therapy? Oftentimes answers to these questions are based more on convention than data. Hence we aim to collect and analyze data to answer these type questions.
Elihu Estey has been added to your "Faculty I'm Following" page in MyF1000
Follow/Unfollow any Faculty via their recommendations, biography pages, or MyF1000